Model performance for PFS in the training cohort and for EFS in the validation cohort
| . | Training cohort (PRIMA) . | Validation cohort (FL2000+MER)* . | |||||
|---|---|---|---|---|---|---|---|
| FLIPI . | PRIMA-PI . | FLIPI2 . | β2m+LDH . | FLIPI . | PRIMA-PI . | β2m+LDH . | |
| Log-rank χ2 | 45.64 | 81.96 | 54.12 | 41.23 | 27.17 | 29.47 | 19.39 |
| CPE (±SE) | 0.577 (±0.011) | 0.604 (±0.011) | 0.577 (±0.010) | 0.572 (±0.011) | 0.605 (±0.020) | 0.606 (±0.019) | 0.577 (±0.017) |
| NRI (±SE) | ref | +36.7% (±6.1%) | +24.7% (±5.8%) | −1.3% (±5.9%) | ref | +3.5% (±8.7%) | −7.1% (±9.8%) |
| . | Training cohort (PRIMA) . | Validation cohort (FL2000+MER)* . | |||||
|---|---|---|---|---|---|---|---|
| FLIPI . | PRIMA-PI . | FLIPI2 . | β2m+LDH . | FLIPI . | PRIMA-PI . | β2m+LDH . | |
| Log-rank χ2 | 45.64 | 81.96 | 54.12 | 41.23 | 27.17 | 29.47 | 19.39 |
| CPE (±SE) | 0.577 (±0.011) | 0.604 (±0.011) | 0.577 (±0.010) | 0.572 (±0.011) | 0.605 (±0.020) | 0.606 (±0.019) | 0.577 (±0.017) |
| NRI (±SE) | ref | +36.7% (±6.1%) | +24.7% (±5.8%) | −1.3% (±5.9%) | ref | +3.5% (±8.7%) | −7.1% (±9.8%) |
The FLIPI2 could not be calculated in the validation cohort because of the unavailable diameter of the longest diameter of the largest involved lymph node with a cutoff set up at 6 cm in the MER cohort.
ref, reference value; SE, standard error.